Physician profile
Alexander Brun
NPI 1164735072
$54,706.35
in general payments reported to CMS, 2019-2025
39 companies · $925 in 2025
The $925 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $11K · 2021: $11K · 2022: $7,286 · 2023: $1,912 · 2024: $2,017 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,854.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,071.29 | 2019-2025 | Mavyret, Linzess, Skyrizi |
| Allergan, INC. | $13,415.96 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,596.91 | 2019-2025 | Xifaxan, Trulance |
| Vivus LLC | $801.24 | 2020-2025 | Pancreaze |
| Gilead Sciences, INC. | $757.14 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $534.59 | 2019-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $502.01 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $494.73 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $483.73 | 2022-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $444.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $401.16 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $375.19 | 2020-2023 | |
| Janssen Biotech, INC. | $341.22 | 2020-2025 | Stelara, Tremfya |
| Redhill Biopharma INC. | $281.07 | 2020-2024 | Talicia |
| Aimmune Therapeutics, INC. | $226.34 | 2024-2025 | Zenpep |
Show all 37 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Brun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.